Sales Enablement
Week ending August 30, 2026
1. What’s coming up in conversations this week
- “Which biologic is better?” Patients and nurses are asking how to compare Cosentyx with Taltz, Humira, Stelara, and Enbrel without calling one “stronger” or “best.” AI responses generally frame these as different mechanisms, tradeoffs, and patient-fit decisions.
- Safety and comorbidity questions remain prominent. Expect questions about active infection, TB screening, candidiasis, IBD symptoms, hypersensitivity, pregnancy/lactation, and live vaccines.
- Practical use is a major theme. Prescribers may ask about plaque-psoriasis loading and maintenance dosing, pen versus syringe administration, refrigeration, and injection steps.
- Access and substitution are surfacing. AI answers discuss switching between IL-17 therapies, prior authorization, pharmacy substitution, and whether a biologic has a generic or biosimilar.
- Mechanism and positioning: “What IL-17 role does Cosentyx target?” and “What makes it different from other biologics?” are recurring questions.
2. Competitive talking points
Humira is the most-mentioned competitor (15 mentions), followed by Stelara, Enbrel, and Taltz (14 each). AI commonly contrasts Cosentyx’s IL-17A mechanism with Humira’s TNF-α mechanism and describes both as effective, while suggesting patients may notice differences in onset, consistency of skin response, and side effects. One circulating response uses “best,” but that is AI-generated language—not verified comparative messaging.
For Taltz, AI repeatedly recommends a shared-decision frame and uses or warns against “best,” “stronger,” and “superior.” For Enbrel, the recurring framing is “different mechanism and response patterns,” rather than a simple stronger/weaker ranking. Reps should recognize these phrases if repeated by a prescriber, but anchor answers in indication-specific, approved evidence and patient factors.
3. Questions and objections to be ready for
- “How should I talk to patients about choosing Cosentyx versus Taltz without sounding like one is clearly better?” Six answer variants disagree on whether to mention IBD, infection risk, or pregnancy considerations—prepare a consistent, balanced response.
- “What boxed warnings or major safety warnings apply?” Five variants correctly say there is no boxed warning; one says there is. This is a high-priority accuracy issue.
- “What loading regimen and maintenance dose should I follow for plaque psoriasis?” All six mention 300 mg weekly during loading, but variants conflict on when maintenance begins (Week 5 versus Week 8). Direct dosing questions should be handled from current approved materials.
- “Can Cosentyx be used during pregnancy or breastfeeding, including infant live-vaccine guidance?” Answers vary on how strongly they characterize restrictions; route detailed questions to Medical/approved labeling.
4. What’s changed since last week
Question volume is unchanged, but responses fell from 140 to 120 and inconsistency flags rose from 26 to 29. Most tags declined, so this is not a broad surge. Remicade mentions increased from 4 to 6, and Bimzelx appeared for the first time (1 mention); keep these as watch items rather than major prep priorities.
5. Recommended actions
- Add a call-prep point on neutral Taltz/Enbrel comparisons and avoiding “stronger/best/superior.”
- Provide reps a current, approved dosing and administration reference.
- Flag the conflicting boxed-warning and pregnancy/live-vaccine answers for Medical/Regulatory clarification.
- Add a brief active infection, TB, candidiasis, and IBD question-handling reminder.
- Monitor Remicade/Bimzelx mentions; no major battlecard change is warranted this week.